580 related articles for article (PubMed ID: 30103241)
1. Genotype-Phenotype Association and Impact on Outcomes following Guided De-Escalation of Anti-Platelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Genotyping Substudy.
Gross L; Trenk D; Jacobshagen C; Krieg A; Gawaz M; Massberg S; Baylacher M; Aradi D; Stimpfle F; Hromek J; Vogelgesang A; Hadamitzky M; Sibbing D; Geisler T
Thromb Haemost; 2018 Sep; 118(9):1656-1667. PubMed ID: 30103241
[TBL] [Abstract][Full Text] [Related]
2. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
3. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
[TBL] [Abstract][Full Text] [Related]
4. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
6. Gender and Outcomes following Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients: The TROPICAL-ACS Gender Substudy.
Gross L; Kupka D; Trenk D; Geisler T; Hadamitzky M; Löw A; Orban M; Huber K; Kiss RG; Merkely B; Huczek Z; Beuthner BE; Hein-Rothweiler R; Baylacher M; Rizas K; Massberg S; Aradi D; Sibbing D; Jacobshagen C
Thromb Haemost; 2019 Sep; 119(9):1527-1538. PubMed ID: 31226717
[TBL] [Abstract][Full Text] [Related]
7. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Stimpfle F; Karathanos A; Droppa M; Metzger J; Rath D; Müller K; Tavlaki E; Schäffeler E; Winter S; Schwab M; Gawaz M; Geisler T
Thromb Res; 2014 Jul; 134(1):105-10. PubMed ID: 24856643
[TBL] [Abstract][Full Text] [Related]
8. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
9. Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Tam CC; Kwok J; Wong A; Yung A; Shea C; Kong SL; Tang WH; Siu D; Chan R; Lee S
J Int Med Res; 2017 Feb; 45(1):134-146. PubMed ID: 28222641
[TBL] [Abstract][Full Text] [Related]
10. Prospective
Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
12. Diurnal Variability of On-Treatment Platelet Reactivity in Clopidogrel versus Prasugrel Treated Acute Coronary Syndrome Patients: A Pre-Specified TROPICAL-ACS Sub-Study.
Freynhofer MK; Hein-Rothweiler R; Haller PM; Aradi D; Dézsi DA; Gross L; Orban M; Trenk D; Geisler T; Huczek Z; Toth-Gayor GG; Massberg S; Huber K; Sibbing D
Thromb Haemost; 2019 Apr; 119(4):660-667. PubMed ID: 30695790
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
Klein MD; Williams AK; Lee CR; Stouffer GA
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
[TBL] [Abstract][Full Text] [Related]
14. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial.
Aradi D; Gross L; Trenk D; Geisler T; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Ruzsa Z; Ungi I; Rizas KD; May AE; Mügge A; Zeiher AM; Holdt L; Huber K; Neumann FJ; Koltowski L; Huczek Z; Hadamitzky M; Massberg S; Sibbing D
Eur Heart J; 2019 Jun; 40(24):1942-1951. PubMed ID: 31226213
[TBL] [Abstract][Full Text] [Related]
15. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
16. Age and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: results from the randomized TROPICAL-ACS trial.
Sibbing D; Gross L; Trenk D; Jacobshagen C; Geisler T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Parma R; Felix SB; Neumann FJ; Hausleiter J; Baylacher M; Koltowski L; Mehilli J; Huber K; Huczek Z; Aradi D; Massberg S;
Eur Heart J; 2018 Aug; 39(29):2749-2758. PubMed ID: 29912422
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Implementation of
Azzahhafi J; Broek WWAVD; Chan Pin Yin DRPP; Harmsze AM; van Schaik RHN; Ten Berg JM
J Cardiovasc Pharmacol Ther; 2023; 28():10742484231210704. PubMed ID: 37899583
[TBL] [Abstract][Full Text] [Related]
18. A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI.
Rath PC; Chidambaram S; Rath P; Dikshit B; Naik S; Sahoo PK; Das B; Mahalingam M; Khandrika L; Jain J
Indian Heart J; 2015; 67(2):114-21. PubMed ID: 26071289
[TBL] [Abstract][Full Text] [Related]
19. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
AlMukdad S; Elewa H; Al-Badriyeh D
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
